Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 369 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Idiopathic Pulmonary Arterial Hypertension Clear all
Completed No phase listed Observational

A Registry for Patients Taking Uptravi

NCT03278002
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 2 Interventional Results available

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

NCT02939599
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
QCC374
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 24, 2026, 2:34 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 24, 2026, 2:34 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Intravenous ZMA001 in Healthy Subjects

NCT05967299
View directory record Official record
Conditions
Pulmonary Arterial Hypertension PAH
Interventions
Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008)
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 4 Interventional Results available

Treprostinil Combined With Tadalafil for Pulmonary Hypertension

NCT01302444
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Portland, Maine • Boston, Massachusetts • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Jul 24, 2026, 2:34 AM EDT
Completed No phase listed Observational

Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH

NCT02631421
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Blood Sampling, Cardiac MRI
Procedure · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Jul 24, 2026, 2:34 AM EDT
Completed No phase listed Observational

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension

NCT05339386
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

NCT03738150
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, SOC
Biological · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Jul 24, 2026, 2:34 AM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

NCT04062565
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Injectable Product, Riociguat Pill
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01725256
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AIR001 (sodium nitrite inhalation solution)
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Ambrisentan in Children 8-18yrs

NCT01332331
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Ambrisentan - low dose, Ambrisentan - high dose
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
8 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 24, 2026, 2:34 AM EDT
Active, not recruiting Not applicable Interventional

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

NCT06477640
View directory record Official record
Conditions
Pulmonary Arterial Hypertension PAH
Interventions
Exercise, Standard of Care
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Completed No phase listed Observational

Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension

NCT05521113
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Home Rehabilitation Monitoring System, Health coaching calls
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Jul 24, 2026, 2:34 AM EDT
Recruiting No phase listed Observational

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

NCT02249923
View directory record Official record
Conditions
Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
New York Medical College
Other
Eligibility
1 Day to 21 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
13
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated No phase listed Observational

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

NCT01494896
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Jul 24, 2026, 2:34 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110
View directory record Official record
Conditions
Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions
LTP, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Active, not recruiting Not applicable Interventional

Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension

NCT06543745
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Frailty
Interventions
Low-Resistance Training
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Oral Sildenafil on Mortality in Adults With PAH

NCT02060487
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
11
States / cities
Atlanta, Georgia • Grand Rapids, Michigan • Wooster, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 3 Interventional

Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension

NCT00159887
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Pulmonary Hypertension and Anastrozole Trial

NCT03229499
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Anastrozole, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Stanford, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

NCT02191137
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
58
States / cities
Tucson, Arizona • La Jolla, California • Moreno Valley, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

NCT00080457
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
sitaxsentan sodium
Drug
Lead sponsor
Encysive Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

NCT01739400
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg tablet, once daily.
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

NCT02279745
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jul 24, 2026, 2:34 AM EDT